Inhibikase Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Inhibikase Therapeutics, Inc. (IKT) reported Basic Shares Outstanding (Weighted Average) of 174.57 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 174.57M shares, a 93.95% increase year-over-year.
- Inhibikase Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 172.31M shares, a 92.44% increase year-over-year.
- Inhibikase Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 123.64M shares, a 71.55% increase year-over-year.
- Inhibikase Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 90.05M shares, a 913.79% increase year-over-year.
- Inhibikase Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 98.31M shares, a 314.60% increase from fiscal 2024.
- Inhibikase Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 23.71M shares, a 293.35% increase from fiscal 2023.
- Inhibikase Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 6.03M shares, a 42.74% increase from fiscal 2022.
- Inhibikase Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 4.22M shares, a 76.81% decline from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 174.57M shares 10-Q · filed 2026-08-11 | 173.45M shares 10-Q · filed 2026-08-11 | 156.84M shares derived: average of 3 quarters · filed 2026-08-11 | 140.14M shares derived: average of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | 172.31M shares 10-Q · filed 2026-05-12 | 147.97M shares derived: average of 2 quarters · filed 2026-05-12 | 128.67M shares derived: average of 3 quarters · filed 2026-05-12 | 119.00M shares derived: average of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | 123.64M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 106.84M shares derived: average of 2 quarters · filed 2026-03-26 | 101.23M shares derived: average of 3 quarters · filed 2026-08-11 | 98.31M shares 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | 90.05M shares 10-Q · filed 2025-11-14 | 90.03M shares derived: average of 2 quarters · filed 2026-08-11 | 89.87M shares 10-Q · filed 2025-11-14 | 85.42M shares derived: average of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | 90.01M shares 10-Q · filed 2026-08-11 | 89.77M shares 10-Q · filed 2026-08-11 | 83.87M shares derived: average of 3 quarters · filed 2026-08-11 | 65.13M shares derived: average of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | 89.54M shares 10-Q · filed 2026-05-12 | 80.80M shares derived: average of 2 quarters · filed 2026-05-12 | 56.83M shares derived: average of 3 quarters · filed 2026-05-12 | 44.51M shares derived: average of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | 72.07M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 40.48M shares derived: average of 2 quarters · filed 2026-03-26 | 29.50M shares derived: average of 3 quarters · filed 2026-03-26 | 23.71M shares 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | 8.88M shares 10-Q · filed 2025-11-14 | 8.21M shares derived: average of 2 quarters · filed 2025-11-14 | 7.59M shares 10-Q · filed 2025-11-14 | 7.92M shares derived: average of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | 7.54M shares 10-Q · filed 2025-08-14 | 6.94M shares 10-Q · filed 2025-08-14 | 7.60M shares derived: average of 3 quarters · filed 2025-08-14 | 7.04M shares derived: average of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | 6.34M shares 10-Q · filed 2025-05-14 | 7.64M shares derived: average of 2 quarters · filed 2025-05-14 | 6.87M shares derived: average of 3 quarters · filed 2025-05-14 | 6.46M shares derived: average of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | 8.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 7.14M shares derived: average of 2 quarters · filed 2025-03-27 | 6.50M shares derived: average of 3 quarters · filed 2025-03-27 | 6.03M shares 10-K · filed 2025-03-27 | 5.33M shares 10-K · filed 2024-03-27 | |||
| 2023-09-30 | 5.34M shares 10-Q · filed 2023-11-14 | 5.28M shares derived: average of 2 quarters · filed 2023-11-14 | 5.06M shares 10-Q · filed 2023-11-14 | 4.84M shares derived: average of 4 quarters · filed 2024-05-15 | ||||
| 2023-06-30 | 5.23M shares 10-Q · filed 2023-08-14 | 4.92M shares 10-Q · filed 2023-08-14 | 4.68M shares derived: average of 3 quarters · filed 2024-05-15 | 4.56M shares derived: average of 4 quarters · filed 2024-05-15 | ||||
| 2023-03-31 | 4.59M shares 10-Q · filed 2024-05-15 | 27.51M shares 10-Q · filed 2023-05-15 | 4.40M shares derived: average of 2 quarters · filed 2024-05-15 | 4.34M shares derived: average of 3 quarters · filed 2024-05-15 | 4.31M shares derived: average of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | 4.22M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | 4.22M shares derived: average of 2 quarters · filed 2024-03-27 | 4.22M shares derived: average of 3 quarters · filed 2024-03-27 | 4.22M shares 10-K · filed 2024-03-27 | 25.21M shares 10-K · filed 2023-03-31 | |||
| 2022-09-30 | 4.22M shares 10-Q · filed 2023-11-14 | 25.23M shares 10-Q · filed 2022-11-14 | 4.22M shares derived: average of 2 quarters · filed 2023-11-14 | 4.22M shares 10-Q · filed 2023-11-14 | 25.22M shares 10-Q · filed 2022-11-14 | 14.72M shares derived: average of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | 4.22M shares 10-Q · filed 2023-08-14 | 25.23M shares 10-Q · filed 2022-08-12 | 4.22M shares 10-Q · filed 2023-08-14 | 25.22M shares 10-Q · filed 2022-08-12 | 18.22M shares derived: average of 3 quarters · filed 2023-08-14 | 19.95M shares derived: average of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | 25.21M shares 10-Q · filed 2023-05-15 | 25.22M shares derived: average of 2 quarters · filed 2023-05-15 | 25.19M shares derived: average of 3 quarters · filed 2023-05-15 | 21.96M shares derived: average of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | 25.23M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 25.19M shares derived: average of 2 quarters · filed 2023-03-31 | 20.87M shares derived: average of 3 quarters · filed 2023-03-31 | 18.21M shares 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | 25.14M shares 10-Q · filed 2022-11-14 | 18.69M shares derived: average of 2 quarters · filed 2022-11-14 | 15.87M shares 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | 12.24M shares 10-Q · filed 2022-08-12 | 11.15M shares 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |